RT Journal Article
SR Electronic
T1 <sup>99m</sup>Tc-Tilmanocept: A Novel Molecular Agent for Lymphatic Mapping and Sentinel Lymph Node Localization
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 87
OP 91
DO 10.2967/jnmt.115.155960
VO 43
IS 2
A1 Surasi, Devaki Shilpa
A1 O’Malley, Janis
A1 Bhambhvani, Pradeep
YR 2015
UL http://tech.snmjournals.org/content/43/2/87.abstract
AB Preoperative lymphatic mapping in conjunction with intraoperative γ-probe detection is widely used for sentinel node localization in melanoma, breast cancer, and other malignancies. 99mTc-radiocolloids have been the standard radiotracers used for sentinel node mapping. 99mTc-tilmanocept is a receptor-binding molecular imaging agent approved by the U.S. Food and Drug Administration for lymphatic mapping and lymph node localization in breast cancer, melanoma, clinically node-negative squamous cell carcinoma of the oral cavity, and other solid tumors. It has several advantages over conventional radiocolloids, including rapid injection site clearance, high sentinel node extraction, and low distal node accumulation, which can lead to efficient resource use.